FOXO4-DRI what is it, in one sentence: a synthetic peptide designed to kill senescent cells by breaking the protein interaction that keeps them alive. It is a senolytic. It is not a growth compound, not a hormone, and not related to anything on the myostatin axis, and almost every misunderstanding about it starts by getting that category wrong.
Key takeaways
- FOXO4 is a natural human protein. FOXO4-DRI is a synthetic peptide designed to interfere with it. They are not the same thing and the names are routinely conflated.
- DRI stands for D-retro-inverso: built from mirror-image amino acids in reversed order, so proteases struggle to break it down.
- It works by displacing FOXO4 from p53, which lets p53 trigger apoptosis in senescent cells while largely sparing healthy ones.
- It came out of a 2017 study at Erasmus MC in Rotterdam and has never progressed to a human trial.
- It has no anabolic action. Interest from a muscle audience is about tissue maintenance, not growth.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
FOXO4-DRI what is it, and what FOXO4 is separately
The naming is genuinely confusing, so it is worth separating the two.
FOXO4 is a protein your body makes. The name stands for Forkhead box protein O4, part of the FOXO family of transcription factors involved in stress resistance, metabolism and cell-cycle control. The fourth character is the letter O, not a zero, which matters because several vendors render it as a digit and the mismatch causes buyers to wonder whether a listing is fake. It is not.
FOXO4-DRI is a laboratory-made peptide, designed to interfere with what FOXO4 does inside senescent cells. It is not something the body produces and it is not a supplement version of a natural protein.
So a search for "FOXO4 vs FOXO4-DRI" is comparing a human transcription factor with a synthetic molecule engineered to disrupt it. One is biology, the other is a tool built to act on that biology.
What D-retro-inverso means
The DRI suffix describes how the peptide is constructed, and it is the reason the molecule is viable at all.
Ordinary peptides are chains of L-amino acids, the form biology uses. They are also, for that reason, exactly what your proteases are built to digest, which gives most therapeutic peptides very short lifespans in the body.
A D-retro-inverso peptide reverses both properties at once. The amino acids are the D form, the mirror image of the natural ones, and the sequence is assembled in reverse order. The combination produces a molecule whose side chains sit in roughly the same spatial arrangement as the original, so it can still engage the same binding partner, while being substantially harder for proteases to recognise and cleave.
That is an established medicinal-chemistry strategy rather than something invented for this compound. It has one analytical consequence worth knowing: because a D-retro-inverso peptide contains the same atoms as its natural counterpart, it has the same mass. Mass spectrometry alone therefore confirms composition but not stereochemistry, which is a detail that matters when reading a certificate of analysis.
How it works
The mechanism is unusually clean to describe, which is part of why the paper attracted so much attention.
Cells that accumulate damage can enter senescence, a permanent exit from the cell cycle. They stop dividing but do not die, and they remain metabolically active, secreting inflammatory cytokines and proteases collectively called the senescence-associated secretory phenotype, or SASP. Senescent cells accumulate with age and their secretions are implicated in chronic low-grade inflammation and declining tissue function.
The puzzle the 2017 work solved was why these cells do not simply undergo apoptosis, given how much damage they carry. The answer was FOXO4. In senescent cells, FOXO4 binds p53 and holds it in the nucleus in a configuration that prevents it from triggering cell death. FOXO4 is, in effect, the reason senescent cells persist.
FOXO4-DRI is a decoy. It occupies the site where FOXO4 would bind p53, displacing the interaction. Freed, p53 relocates out of the nucleus and the cell undergoes apoptosis. Healthy cells, which are not relying on that interaction for survival, are largely unaffected, and that differential is what makes the compound selective. A 2025 paper in Nature Communications characterised the binding target more precisely as the disordered transactivation domain of p53.
Where it came from, and where it stopped
The origin is Baar and colleagues, Cell, 2017, from Peter de Keizer's group at Erasmus University Medical Center in Rotterdam, with collaborators including Judith Campisi at the Buck Institute.
The paper reported that the peptide neutralised doxorubicin-induced chemotoxicity in mice, and restored fitness, fur density and renal function in both fast-ageing XpdTTD/TTD mice and naturally aged animals. It was covered widely in the general press, which is largely why the compound has a public profile at all.
Since then, other groups have applied it in their own models: aged mouse Leydig cells and testosterone, spermatogenesis in aged mice, keloid fibroblasts, murine pulmonary fibrosis, and human chondrocytes in culture. The mechanistic understanding has deepened.
What has not happened is a human trial. Nine years after the founding paper there is no registered interventional study of FOXO4-DRI in people, no regulatory approval anywhere, and no established human dose. The compound is best understood as a well-characterised preclinical tool rather than an emerging therapy.
Why a muscle site covers it, and the line it will not cross
Senescent cells accumulate in ageing skeletal muscle. Their inflammatory secretions are part of why satellite cells, the resident repair population, respond less effectively to damage in older animals. Sarcopenia is not only anabolic signalling declining; the environment that repair happens in degrades as well. A compound that clears senescent cells addresses that second problem in principle, which is the honest reason this audience might follow the research.
The line: FOXO4-DRI is not anabolic. It does not act on myostatin, activin or follistatin, does not stimulate protein synthesis, and no study in any species has measured hypertrophy, strength or lean mass. Maintenance of tissue quality and promotion of growth are different claims. If growth pathways are what you are after, the muscle-growth peptide guide and the follistatin material are the relevant reading.
It is also worth knowing that senolysis is not uniformly beneficial. Senescence suppresses tumour formation and contributes to wound healing, and a 2023 study in Circulation found clearing senescent cells could worsen pulmonary hypertension.
Frequently asked questions
What does FOXO4-DRI stand for?
Forkhead box protein O4, D-Retro-Inverso. The first part names the protein the peptide is modelled on and targets; the second describes its construction from D-amino acids in reversed sequence, which makes it resistant to protease degradation.
What is the difference between FOXO4 and FOXO4-DRI?
FOXO4 is a natural human transcription factor. FOXO4-DRI is a synthetic peptide built to disrupt what FOXO4 does in senescent cells, by displacing it from p53. One is part of your biology, the other is a laboratory tool designed to interfere with it.
What does a senolytic do?
It selectively kills senescent cells, which accumulate with age, no longer divide, and secrete inflammatory signals. The aim is removal of that population rather than ongoing suppression of a pathway, which is why senolytic dosing in the animal work was short and intermittent.
Is FOXO4-DRI approved or in trials?
Neither. It has no approval from the FDA, EMA or MHRA, and ClinicalTrials.gov lists no registered interventional study of it in humans. All published evidence comes from animals or cultured cells.
Why is it sometimes written FOX04?
A typo that spread, including into some vendor product URLs. The correct fourth character is the letter O, from Forkhead box protein O4. Listings using a zero are generally the same material, but it is worth recognising so a spelling mismatch does not read as a counterfeit signal.